What is Taiko Pharmaceutical Co Cash Flow from Financing?
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2024,
Taiko Pharmaceutical Co paid円0 Mil more to buy back shares than it received from issuing new shares.
It received円0 Mil from issuing more debt.
It paid円0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received円0 Mil from paying cash dividends to shareholders.
It received円0 Mil on other financial activities.
In all, Taiko Pharmaceutical Cospent円0 Mil on financial activities for the
three
months ended in Mar. 2024.
Taiko Pharmaceutical Co Cash Flow from Financing Historical Data
The historical data trend for Taiko Pharmaceutical Co's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Taiko Pharmaceutical Co Cash Flow from Financing Chart
Taiko Pharmaceutical Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Taiko Pharmaceutical Co's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiko Pharmaceutical Co (TSE:4574) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Taiko Pharmaceutical Co's issuance of stock for the
three
months ended in Mar. 2024 was 円0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Taiko Pharmaceutical Co's repurchase of stock for the
three
months ended in Mar. 2024 was 円0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Taiko Pharmaceutical Co's net issuance of debt for the
three
months ended in Mar. 2024 was 円0 Mil.
Taiko Pharmaceutical Co received円0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Taiko Pharmaceutical Co's net issuance of preferred for the
three
months ended in Mar. 2024 was 円0 Mil.
Taiko Pharmaceutical Co paid円0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Taiko Pharmaceutical Co's cash flow for dividends for the
three
months ended in Mar. 2024 was 円0 Mil.
Taiko Pharmaceutical Co received円0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Taiko Pharmaceutical Co's other financing for the
three
months ended in Mar. 2024 was 円0 Mil.
Taiko Pharmaceutical Co received円0 Mil on other financial activities.
Taiko Pharmaceutical Co Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Taiko Pharmaceutical Co (TSE:4574) Business Description
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4574 has been successfully added to your 